Spots Global Cancer Trial Database for Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
Official Title: Dose Finding Phase 1 Study of the Treatment of Metastatic Melanoma With MPC-6827 in Combination With Temozolomide
Study ID: NCT00609011
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, determination of dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with temozolomide.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Angeles Clinic, Los Angeles, California, United States
Cancer Centers of Florida, Ocoee, Florida, United States
Cancer Centers of the Carolinas, Greenville, South Carolina, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Contact Details
Name: Andrew P. Beelen, MD
Affiliation: Myrexis Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
